Transfer of autoimmune diabetes from diabetic NOD mice to NOD athymic nude mice: the roles of T cell subsets in the pathogenesis. 1993

M Matsumoto, and H Yagi, and K Kunimoto, and J Kawaguchi, and S Makino, and M Harada
Shionogi Research Laboratories, Shionogi & Co., Ltd., Osaka, Japan.

The NOD mouse, which spontaneously develops insulitis and overt diabetes, is a model of autoimmune type I diabetes mellitus. To analyze of the roles of CD4+ and CD8+ T cells in the pathogenesis of this mouse, we have been doing a series of studies on the induction of insulitis and diabetes in NOD athymic nude mice by means of T cell transfer. To complement our previous study dealing with the induction of insulitis and cyclophosphamide-induced diabetes in recipients that had been reconstituted with each T cell subset derived from the nondiabetic mice, the present study was conducted to observe the transfer of spontaneous diabetes by injecting T cells harvested from diabetic mice. Any possible in vivo increase in the contaminating T cell subset was prevented by injecting the antibody homologous to it. Transfer of untreated or complement-treated splenic lymphocytes of diabetic mice containing both T cell subsets induced spontaneous diabetes 30 to 58 days after the cell transfer as well as insulitis, while spleen cells from nondiabetic mice rarely produced diabetes. On the other hand, transfer of either CD4+ cell-depleted or CD8+ cell-depleted splenic lymphocytes of diabetic mice did not cause diabetes at least up to 60 days after the cell transfer. Also, transfer of only the CD4+ T cell-depleted fraction did not cause insulitis. In contrast, transfer of only the CD8+ T cell-depleted fraction induced insulitis in all the recipients. However, insulitis was less potent in this group of mice than in the diabetic recipients given both subsets: only a low insulitis score was obtained and a number of beta-cells remained alive despite the insulitis in mice given the CD8+ T cell-depleted fraction, whereas islet damage was very severe and insulin-secreting beta-cells were no longer detected in the diabetic mice. Thus, the present results agree with the previous ones concerning transfer of diabetes, with the aid of cyclophosphamide treatment, by T cells of nondiabetic mouse origin. Consideration of our results together with earlier findings led to the conclusion that CD4+ T cells are primarily responsible for insulitis and that CD8+ T cells migrate into islets and are differentiated into mature killer cells against beta-cells with the aid of CD4+ T cells in both spontaneous and cyclophosphamide-induced diabetes.

UI MeSH Term Description Entries
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D008297 Male Males
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte

Related Publications

M Matsumoto, and H Yagi, and K Kunimoto, and J Kawaguchi, and S Makino, and M Harada
May 1989, The Journal of experimental medicine,
M Matsumoto, and H Yagi, and K Kunimoto, and J Kawaguchi, and S Makino, and M Harada
August 1986, Diabetes,
M Matsumoto, and H Yagi, and K Kunimoto, and J Kawaguchi, and S Makino, and M Harada
April 1997, Proceedings of the National Academy of Sciences of the United States of America,
M Matsumoto, and H Yagi, and K Kunimoto, and J Kawaguchi, and S Makino, and M Harada
September 1994, Journal of immunology (Baltimore, Md. : 1950),
M Matsumoto, and H Yagi, and K Kunimoto, and J Kawaguchi, and S Makino, and M Harada
July 1996, Experimental animals,
M Matsumoto, and H Yagi, and K Kunimoto, and J Kawaguchi, and S Makino, and M Harada
January 2016, Methods in molecular biology (Clifton, N.J.),
M Matsumoto, and H Yagi, and K Kunimoto, and J Kawaguchi, and S Makino, and M Harada
October 1987, The Journal of experimental medicine,
M Matsumoto, and H Yagi, and K Kunimoto, and J Kawaguchi, and S Makino, and M Harada
October 1986, Jikken dobutsu. Experimental animals,
M Matsumoto, and H Yagi, and K Kunimoto, and J Kawaguchi, and S Makino, and M Harada
June 1986, Journal of immunology (Baltimore, Md. : 1950),
M Matsumoto, and H Yagi, and K Kunimoto, and J Kawaguchi, and S Makino, and M Harada
January 1992, JPEN. Journal of parenteral and enteral nutrition,
Copied contents to your clipboard!